Immunoradiometric assay of atrial natriuretic peptide in unextracted plasma

1990 ◽  
Vol 36 (6) ◽  
pp. 855-859 ◽  
Author(s):  
J E Tattersall ◽  
A Dawnay ◽  
C McLean ◽  
W R Cattell
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Normal Subjects ◽  
Disulfide Bridge ◽  
Immunoradiometric Assay ◽  
Assay Sensitivity ◽  
Standard Curve ◽  
Hook Effect ◽  
C Terminus ◽  
Atrial Natriuretic

Abstract We have developed and validated a two-site liquid-phase immunoradiometric assay (IRMA) of atrial natriuretic peptide (ANP) in unextracted human plasma. Both radiolabeled rabbit anti-ANP IgG and polyclonal mouse anti-ANP must bind to ANP for detection, and the assay is specific for peptides with both an intact C-terminus and a disulfide bridge. The assay sensitivity (detection limit) is 0.96 pmol/L, and the working range is 2.3-300 pmol/L, with the hook effect occurring above 500 pmol/L. Results for diluted plasma from normal subjects and from patients with renal failure paralleled the standard curve; analytical recovery of ANP added to such samples averaged 94%. The between- and within-assay CVs at 8 pmol/L were 10% and 5%, respectively. The assay is sufficiently sensitive and precise to detect the postural change in ANP concentrations in normal subjects.

Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide

2004 ◽  
Vol 42 (1) ◽  
Author(s):  
Concetta Prontera ◽  
Michele Emdin ◽  
Gian CarloZucchelli ◽  
Andrea Ripoli ◽  
Claudio Passino ◽  
...  
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Diagnostic Accuracy ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Normal Subjects ◽  
Analytical Performance ◽  
Immunoradiometric Assay ◽  
Terminal Fragment ◽  
Assay Methods ◽  
Atrial Natriuretic

AbstractWe evaluated the analytical performance of a fully-automated electrochemiluminescence “sandwich” immunoassay method for the N-terminal fragment of the pro-peptide of brain natriuretic peptide (BNP). We then compared the diagnostic accuracy of this method in discriminating between normal subjects and patients with cardiomyopathy with that found with two previously described immunoradiometric assay methods for the assay of atrial natriuretic peptide (ANP) and BNP. We studied 193 consecutive patients (mean age 64.4±12.3 years, range 20–89 years, including 56 women and 137 men) with chronic cardiomyopathy and a group of 85 healthy subjects (mean age 52.3±12.0 years, 42 women and 43 men, range 20–79 years). N-terminal fragment of proBNP

Hemodynamic and renal effects following bolus injection of atrial natriuretic peptide (α-hANP) in normal subjects

1988 ◽  
Vol 117 (4_Suppl) ◽  
pp. S235-S236
Author(s):  
G. MÜLLER-ESCH ◽  
J. POTRATZ ◽  
W. KLINGLER ◽  
R. GERZER ◽  
R. LAWRENZ ◽  
...  
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Bolus Injection ◽  
Normal Subjects ◽  
Renal Effects ◽  
Atrial Natriuretic

Radioimmunoassays of Arginine Vasopressin and Atrial Natriuretic Peptide: Application of a Common Protocol for Plasma Extraction Using Sep-Pak C18 Cartridges

1992 ◽  
Vol 29 (6) ◽  
pp. 652-658 ◽  
Author(s):  
M D Penney ◽  
D Hampton ◽  
D A Oleesky ◽  
C Livingstone ◽  
E Mulkerrin
Keyword(s):  
Standard Deviation ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Arginine Vasopressin ◽  
Normal Subjects ◽  
Positive Pressure ◽  
Aqueous Methanol ◽  
Simultaneous Extraction ◽  
Plasma Extraction ◽  
Atrial Natriuretic

A rapid vacuum-driven procedure, using pre-treated Sep-Pak C18 cartridges, has been developed for the simultaneous extraction of arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) from plasma. Non-specific interference was removed by fractional elution with an aqueous methanol/trifluoroacetic acid (TFA) mixture. AVP and ANP were coeluted under positive pressure with a methanol/TFA mixture and the eluates air-dried before measurement using separate radioimmunoassays. Assay ranges for AVP and ANP were 0·12–29·5 pmol/L and 0·65–162 pmol/L, respectively, with mean recoveries (standard deviation in parentheses) for AVP of 96·4% (5·5%) at a level of 11·8 pmol/L and for ANP of 94·8% (5·9%) at a level of 32·4 pmol/L. The extraction and assay procedures were validated by observing the changes in plasma AVP and ANP concentrations in normal subjects at different stages of hydration and in elderly patients during treatment for congestive cardiac failure.

Effect of atrial natriuretic peptide on catecholamine release from human pheochromocytoma

1989 ◽  
Vol 120 (1) ◽  
pp. 107-112 ◽  
Author(s):  
Mitsuaki Nakamaru ◽  
Toshio Ogihara ◽  
Hiroshi Saito ◽  
Hiromi Rakugi ◽  
Kiyoko Hashizume ◽  
...  
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Direct Action ◽  
Plasma Catecholamines ◽  
Normal Subjects ◽  
Catecholamine Release ◽  
Plasma Norepinephrine ◽  
Atrial Natriuretic

Abstract. The effect of synthetic alpha human atrial natriuretic peptide on catecholamine release from human pheochromocytomas was studied both in vivo and in vitro. Iv infusion of atrial natriuretic peptide at a rate of 0.1 μg ·kg−1·min−1 for 60 min into two normotensive patients with pheochromocytoma caused a small decrease in the mean blood pressure, increase in the heart rate, and marked increase in the plasma level of norepinephrine (2.08 to 6.83 nmol/l, and 1.15 to 2.83 nmol/l, respectively) compared with 0.60 ± 0.10 to 1.19 ± 0.20 nmol/l in normal subjects. Treatment with atrial natriuretic peptide also increased the plasma epinephrine level from 0.34 to 1.27 nmol/l, and from 0.67 to 0.79 nmol/l in the patients with pheochromocytoma, but not in the normal subjects (0.05 ± 0.01 to 0.05 ± 0.01 nmol/l). After removal of the tumour, the responses of the plasma norepinephrine and epinephrine to atrial natriuretic peptide infusion were normalized. There was no significant effect of 10−8 to 10−5 mol/l atrial natriuretic peptide on the basal release of catecholamines from isolated superfused pheochromocytoma tissue. Atrial natriuretic peptide (10−7 mol/l) did not affect the increase in catecholamine release induced by glucagon (10−5 mol/l). These results suggest that the exaggerated responses of plasma catecholamines to atrial natriuretic peptide in patients with pheochromocytoma may be due to a washout effect resulting from change in blood flow in the vessels feeding the tumour rather than increased sympathetic nerve activity induced by hypotension and hypovolemia. The results also suggest that atrial natriuretic peptide dose not have any direct action on pheochromocytoma tissue causing catecholamine release.

The plasma release of atrial natriuretic peptide in man

1986 ◽  
Vol 71 (2) ◽  
pp. 151-155 ◽  
Author(s):  
J. V. Anderson ◽  
J. Donckier ◽  
W. J. McKenna ◽  
S. R. Bloom
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Pressure Rise ◽  
Plasma Osmolality ◽  
Normal Subjects ◽  
Solution Saline ◽  
The Mean ◽  
Maximal Rise ◽  
Important Stimulus ◽  
Atrial Natriuretic

1. We studied plasma atrial natriuretic peptide (ANP) concentrations in seven normal subjects after the acute intravenous infusion of sodium chloride/potassium chloride solution (saline). 2. Three separate infusions of 6, 12 and 18 ml of saline/kg body weight each significantly increased the circulating concentration of ANP without changes of plasma osmolality or electrolyte concentrations. 3. The mean maximal rise of the plasma ANP concentration after the three saline infusions was significantly correlated (r = 0.74, P < 0.001) with, but occurred 10–30 min later than, the maximal atrial pressure rise. 4. These observations are in accord with the hypotheses that: (a) ANP is a circulating natriuretic factor; (b) atrial distension is an important stimulus to ANP release in man.

Circadian Rhythms of Atrial Natriuretic Peptide, Blood Pressure and Heart Rate in Normal Subjects

Cardiology ◽  
1989 ◽  
Vol 76 (6) ◽  
pp. 428-432 ◽  
Author(s):  
Francesco Portaluppi ◽  
Loris Montanari ◽  
Bruno Bagni ◽  
Ettore degli Uberti ◽  
Giorgio Trasforini ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Circadian Rhythms ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Normal Subjects ◽  
Atrial Natriuretic

Plasma levels of atrial natriuretic peptide under acute hypoxia in normal subjects

1989 ◽  
Vol 76 (1) ◽  
pp. 79-91 ◽  
Author(s):  
A. Kawashima ◽  
K. Kubo ◽  
K. Hirai ◽  
S. Yoshikawa ◽  
Y. Matsuzawa ◽  
...  
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Acute Hypoxia ◽  
Normal Subjects ◽  
Atrial Natriuretic

Atrial natriuretic peptide: an endogenous factor enhancing sodium excretion in man

1986 ◽  
Vol 70 (4) ◽  
pp. 327-331 ◽  
Author(s):  
John Anderson ◽  
Allan Struthers ◽  
Nic Christofides ◽  
Stephen Bloom
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Sodium Excretion ◽  
Cardiac Tissue ◽  
Normal Subjects ◽  
Haemodynamic Changes ◽  
Calculated Dose ◽  
Human Cardiac Tissue ◽  
Incremental Concentration ◽  
Atrial Natriuretic

1. For many years experimental evidence has suggested the existence of a circulating factor able to enhance sodium excretion. 2. Very recently peptides with natriuretic activity in experimental animals have been isolated from mammalian and human cardiac tissue. In order to determine whether this natriuretic activity has relevance to man we have studied the effects of an infusion of α-human atrial natriuretic peptide (α-h-ANP) in normal subjects. 3. Sodium excretion trebled (P = <0.005) during the infusion of a calculated dose of 15 pmol of α-h-ANP min−1 kg−1 and there was an accompanying diuresis; radioimmunoassay of plasma α-h-ANP during the natriuresis indicated a mean peak incremental concentration of 203 ± 78 (sem) pmol/l. The infusion of a calculated dose of 1.5 pmol min−1 kg−1 did not affect sodium excretion. 4. There were no haemodynamic changes and no side effects were noted.

Effects of an oral water load and intravenous administration of isotonic glucose, hypertonic saline, mannitol and furosemide on the release of atrial natriuretic peptide in men

1988 ◽  
Vol 119 (2) ◽  
pp. 269-276 ◽  
Author(s):  
Yasuhiro Yamasaki ◽  
Takeshi Nishiuchi ◽  
Akihiro Kojima ◽  
Haruhiko Saito ◽  
Shiro Saito
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Hypertonic Saline ◽  
Natriuretic Peptide ◽  
Plasma Volume ◽  
Normal Subjects ◽  
Water Load ◽  
Age Related ◽  
The Mean ◽  
Hypertonic Saline Infusion ◽  
Atrial Natriuretic

Abstract. The effects of an oral water load and iv administration of isotonic glucose, hypertonic saline, mannitol and furosemide on release of human atrial natriuretic peptide (hANP) were examined in normal subjects to determine the main factors causing its release. In addition, the influence of age on hANP secretion was investigated. The mean plasma hANP level in normal subjects, 0–89 years old, was 20.6 ± 1.1 ng/l (mean ± sem) and showed age-related change. The plasma hANP level did not change significantly after a water load or infusion of isotonic glucose, but rose significantly from 11.4 ± 1.4 to 15.6 ± 3.2 ng/l after infusion of hypertonic saline and from 10.9 ± 1.6 to 17.8 ± 4.1 ng/l after infusion of 20% mannitol in parallel with the increase in plasma volume. The plasma hANP level decreased from 17.3 ± 2.5 to 9.0 ± 2.5 ng/l after injection of 40 mg of furosemide. A positive correlation was found between change in the plasma hANP level and percent change in the plasma volume (P < 0.001) on these treatments. The response of plasma hANP to hypertonic saline infusion was greater in older than in young men. These results indicate that 1) the secretion of hANP shows an age-related change and 2) increase in the circulating plasma volume is an important factor regulating hANP secretion.

Sign in / Sign up

Export Citation Format

Share Document